- Home
- FFA vs NGNE Comparison
FFA vs NGNE Comparison
Compare FFA & NGNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FFA
- NGNE
- Stock Information
- Founded
- FFA 2004
- NGNE 2003
- Country
- FFA United States
- NGNE United States
- Employees
- FFA N/A
- NGNE N/A
- Industry
- FFA Investment Managers
- NGNE Biotechnology: Pharmaceutical Preparations
- Sector
- FFA Finance
- NGNE Health Care
- Exchange
- FFA Nasdaq
- NGNE Nasdaq
- Market Cap
- FFA 416.1M
- NGNE 426.6M
- IPO Year
- FFA N/A
- NGNE N/A
- Fundamental
- Price
- FFA $21.41
- NGNE $20.46
- Analyst Decision
- FFA
- NGNE Strong Buy
- Analyst Count
- FFA 0
- NGNE 6
- Target Price
- FFA N/A
- NGNE $38.50
- AVG Volume (30 Days)
- FFA 26.1K
- NGNE 255.3K
- Earning Date
- FFA 01-01-0001
- NGNE 11-13-2025
- Dividend Yield
- FFA 6.72%
- NGNE N/A
- EPS Growth
- FFA N/A
- NGNE N/A
- EPS
- FFA N/A
- NGNE N/A
- Revenue
- FFA N/A
- NGNE N/A
- Revenue This Year
- FFA N/A
- NGNE N/A
- Revenue Next Year
- FFA N/A
- NGNE N/A
- P/E Ratio
- FFA N/A
- NGNE N/A
- Revenue Growth
- FFA N/A
- NGNE N/A
- 52 Week Low
- FFA $15.84
- NGNE $6.88
- 52 Week High
- FFA $19.30
- NGNE $37.27
- Technical
- Relative Strength Index (RSI)
- FFA 49.35
- NGNE 35.53
- Support Level
- FFA $20.85
- NGNE $19.68
- Resistance Level
- FFA $21.54
- NGNE $22.42
- Average True Range (ATR)
- FFA 0.31
- NGNE 2.73
- MACD
- FFA -0.06
- NGNE -1.15
- Stochastic Oscillator
- FFA 55.39
- NGNE 6.16
About FFA First Trust Enhanced Equity Income Fund
First Trust Enhanced Equity Income Fund is a diversified, closed-end management investment company. Its investment objective is to provide high level of current income and gains and, to a lesser extent, capital appreciation. The Fund pursues its investment objective by investing in a diversified portfolio of equity securities.
About NGNE Neurogene Inc.
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACTTM (Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.